ALLO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 24.30%

Insider Buying (Last 12 Months): $4,999,997.30

Insider Selling (Last 12 Months): $260,502.61

Allogene Therapeutics Insider Trading History Chart

Allogene Therapeutics Share Price & Price History

^$1.55

▼ -0.01 (-0.64%)

As of 03/28/2025 05:00 PM ET

Days: 30 | 90 | 365

Allogene Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/14/2025	Benjamin Machinas Beneski	SVP	Sell	5,488	$1.98	$10,866.24	218,507
3/14/2025	David D Chang	CEO	Sell	46,668	$1.96	$91,469.28	5,276,569
2/3/2025	Earl Martin Douglas	SVP	Sell	6,404	$1.71	$10,950.84	587,848
2/3/2025	Geoffrey M Parker	CFO	Sell	4,361	$1.73	$7,544.53	1,301,540
2/3/2025	Timothy L Moore	Insider	Sell	14,746	$1.71	$25,215.66	250,713
1/21/2025	Zachary Roberts	EVP	Sell	27,199	$1.78	$48,414.22	488,054
12/9/2024	Deborah M Messemer	Director	Sell	9,136	$2.18	$19,916.48	157,629
12/5/2024	Franz B Humer	Director	Sell	9,221	$2.16	$19,917.36	307,507
5/30/2024	Franz B Humer	Director	Sell	11,200	$2.34	$26,208.00	255,253
5/16/2024	Arie Belldegrun	Director	Buy	1,724,137	$2.90	$4,999,997.30	1,724,137
1/30/2024	Geoffrey M Parker	CFO	Buy	190	$3.60	$684.00	819,590
12/18/2023	Deborah M Messemer	Director	Sell	18,640	$2.70	$50,328.00	62,456
8/7/2023	Stephen Mayo	Director	Sell	10,000	$4.29	$42,900.00	25,328
2/13/2023	Veer Bhavnagri	General Counsel	Sell	3,000	$6.85	$20,550.00	577,677
1/17/2023	Veer Bhavnagri	General Counsel	Sell	3,000	$7.04	$21,120.00	580,677
12/15/2022	Veer Bhavnagri	General Counsel	Sell	5,602	$7.53	$42,183.06	583,677
8/11/2022	Owen N. Witte	Director	Sell	10,000	$16.50	$165,000.00	223,271
8/2/2022	Rafael Amado	CMO	Sell	2,000	$11.97	$23,940.00	540,257
7/5/2022	Rafael Amado	CMO	Sell	2,000	$11.44	$22,880.00	542,257
6/22/2022	Owen N. Witte	Director	Sell	10,000	$11.76	$117,600.00	233,271
6/21/2022	Rafael Amado	CMO	Sell	2,000	$11.18	$22,360.00	544,257
5/19/2022	Rafael Amado	CMO	Sell	11,500	$7.40	$85,100.00	546,257

See Full Table

SEC Filings (Institutional Ownership Changes) for Allogene Therapeutics (NASDAQ:ALLO)

83.63% of Allogene Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Allogene Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/18/2025	California State Teachers Retirement System	135,554	$0.29M	0.0%	+6.0%	0.065%
2/18/2025	Navalign LLC	59,865	$0.13M	0.0%	-20.6%	0.029%
2/17/2025	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	270,559	$0.58M	0.0%	+18.2%	0.129%
2/17/2025	Squarepoint Ops LLC	20,345	$43K	0.0%	-89.2%	0.010%
2/17/2025	Two Sigma Advisers LP	2,702,200	$5.76M	0.0%	+12.1%	1.289%
2/17/2025	Two Sigma Investments LP	2,712,139	$5.78M	0.0%	-3.1%	1.294%
2/17/2025	Tidal Investments LLC	135,952	$0.29M	0.0%	-4.8%	0.065%
2/17/2025	Rafferty Asset Management LLC	367,445	$0.78M	0.0%	+15.9%	0.175%
2/17/2025	Raiffeisen Bank International AG	430,000	$0.90M	0.0%	N/A	0.205%
2/17/2025	ProShare Advisors LLC	46,082	$98K	0.0%	+25.6%	0.022%
2/17/2025	Patient Square Capital LP	1,489,909	$3.17M	1.2%	N/A	0.711%
2/17/2025	Nuveen Asset Management LLC	300,871	$0.64M	0.0%	+18.3%	0.143%
2/17/2025	MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.	305,895	$0.65M	0.0%	+23.6%	0.146%
2/17/2025	Graham Capital Management L.P.	41,737	$89K	0.0%	N/A	0.020%
2/17/2025	Coastal Bridge Advisors LLC	221,059	$0.47M	0.1%	-45.5%	0.105%
2/17/2025	D. E. Shaw & Co. Inc.	54,517	$0.12M	0.0%	-39.6%	0.026%
2/17/2025	DAFNA Capital Management LLC	1,240,118	$2.64M	0.7%	+18.1%	0.591%
2/17/2025	Caption Management LLC	15,000	$32K	0.0%	N/A	0.007%
2/17/2025	Brevan Howard Capital Management LP	87,573	$0.19M	0.0%	+38.9%	0.042%
2/17/2025	Caxton Associates LP	206,380	$0.44M	0.0%	-14.8%	0.098%
2/17/2025	Bank of America Corp DE	1,163,743	$2.48M	0.0%	+99.3%	0.555%
2/17/2025	BNP Paribas Financial Markets	849,658	$1.81M	0.0%	+1,732.2%	0.405%
2/17/2025	Ameriprise Financial Inc.	201,943	$0.43M	0.0%	+14.0%	0.096%
2/14/2025	Jane Street Group LLC	164,523	$0.35M	0.0%	-63.5%	0.078%
2/14/2025	Foresite Capital Management VI LLC	3,448,275	$7.35M	3.3%	N/A	1.645%
2/14/2025	Northern Trust Corp	1,305,232	$2.78M	0.0%	+4.5%	0.623%
2/14/2025	Lynx1 Capital Management LP	10,874,723	$23.16M	8.7%	+75.3%	5.187%
2/14/2025	Susquehanna Fundamental Investments LLC	376,661	$0.80M	0.0%	N/A	0.180%
2/14/2025	Syon Capital LLC	18,351	$39K	0.0%	N/A	0.009%
2/14/2025	Price T Rowe Associates Inc. MD	4,485,572	$9.56M	0.0%	-7.3%	2.139%
2/14/2025	Hsbc Holdings PLC	69,155	$0.15M	0.0%	+32.0%	0.033%
2/14/2025	MetLife Investment Management LLC	38,020	$81K	0.0%	-28.5%	0.018%
2/14/2025	Dimensional Fund Advisors LP	3,561,626	$7.59M	0.0%	+30.4%	1.699%
2/14/2025	Gilead Sciences Inc.	1,156,689	$2.46M	0.2%	N/A	0.552%
2/13/2025	Zacks Investment Management	480,874	$1.02M	0.0%	-6.9%	0.229%
2/13/2025	XTX Topco Ltd	158,537	$0.34M	0.0%	N/A	0.076%
2/13/2025	Barclays PLC	761,286	$1.62M	0.0%	+122.0%	0.363%
2/13/2025	Renaissance Technologies LLC	554,541	$1.18M	0.0%	-13.6%	0.264%
2/13/2025	Legal & General Group Plc	112,235	$0.24M	0.0%	-11.9%	0.054%
2/13/2025	Invesco Ltd.	127,486	$0.27M	0.0%	+7.0%	0.061%
2/13/2025	Cerity Partners LLC	387,387	$0.83M	0.0%	-10.4%	0.185%
2/13/2025	Wells Fargo & Company MN	104,593	$0.22M	0.0%	+29.4%	0.050%
2/12/2025	PAX Financial Group LLC	12,832	$27K	0.0%	N/A	0.006%
2/12/2025	RPO LLC	14,787	$31K	0.0%	N/A	0.007%
2/12/2025	JPMorgan Chase & Co.	3,736,132	$7.96M	0.0%	-8.6%	1.782%
2/12/2025	Mitsubishi UFJ Asset Management Co. Ltd.	253,576	$0.55M	0.0%	+7.1%	0.121%
2/11/2025	Vanguard Group Inc.	8,000,692	$17.04M	0.0%	-3.9%	3.816%
2/11/2025	KLP Kapitalforvaltning AS	20,400	$43K	0.0%	N/A	0.010%
2/11/2025	Sei Investments Co.	48,320	$0.10M	0.0%	N/A	0.023%
2/11/2025	American Century Companies Inc.	232,356	$0.50M	0.0%	+16.5%	0.111%
2/11/2025	Teacher Retirement System of Texas	43,877	$93K	0.0%	+28.9%	0.021%
2/11/2025	Intech Investment Management LLC	71,323	$0.15M	0.0%	+72.6%	0.034%
2/10/2025	Primecap Management Co. CA	4,927,340	$10.50M	0.0%	-13.1%	2.350%
2/10/2025	Cibc World Markets Corp	12,013	$26K	0.0%	N/A	0.006%
2/10/2025	Swiss National Bank	287,900	$0.61M	0.0%	+8.7%	0.137%
2/7/2025	HighTower Advisors LLC	12,150	$26K	0.0%	-59.0%	0.006%
2/6/2025	Charles Schwab Investment Management Inc.	1,188,838	$2.53M	0.0%	+0.8%	0.567%
2/4/2025	Bank of New York Mellon Corp	330,769	$0.71M	0.0%	+4.1%	0.158%
1/31/2025	Partners Capital Investment Group LLP	93,248	$0.20M	0.0%	-63.4%	0.044%
1/30/2025	Rhumbline Advisers	191,714	$0.41M	0.0%	+10.1%	0.091%
1/30/2025	Vontobel Holding Ltd.	195,457	$0.42M	0.0%	+788.4%	0.093%
1/24/2025	abrdn plc	364,382	$0.78M	0.0%	N/A	0.174%
1/17/2025	Bourgeon Capital Management LLC	118,700	$0.25M	0.0%	-16.7%	0.057%
1/6/2025	Nordea Investment Management AB	460,641	$0.99M	0.0%	+2.1%	0.220%
12/26/2024	JPMorgan Chase & Co.	4,087,506	$11.45M	0.0%	-0.9%	1.949%
11/25/2024	Tidal Investments LLC	142,747	$0.40M	0.0%	-39.7%	0.068%
11/19/2024	Barclays PLC	342,973	$0.96M	0.0%	+101.5%	0.164%
11/16/2024	Geode Capital Management LLC	3,227,104	$9.04M	0.0%	+14.4%	1.539%
11/15/2024	Barclays PLC	342,973	$0.96M	0.0%	+101.5%	0.164%
11/15/2024	MML Investors Services LLC	20,000	$56K	0.0%	N/A	0.010%
11/15/2024	Zacks Investment Management	516,601	$1.45M	0.0%	N/A	0.246%
11/15/2024	EP Wealth Advisors LLC	24,475	$69K	0.0%	+125.6%	0.012%
11/15/2024	State Street Corp	7,013,083	$19.64M	0.0%	-8.5%	3.345%
11/15/2024	Erste Asset Management GmbH	31,400	$91K	0.0%	N/A	0.015%
11/14/2024	Vestal Point Capital LP	1,500,000	$4.20M	0.3%	-31.8%	0.715%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	228,806	$0.64M	0.0%	-14.2%	0.109%
11/14/2024	MetLife Investment Management LLC	53,147	$0.15M	0.0%	-10.1%	0.025%
11/13/2024	BNP Paribas Financial Markets	46,374	$0.13M	0.0%	+541.5%	0.022%
11/13/2024	FMR LLC	30,026,956	$84.08M	0.0%	-3.9%	14.321%
11/13/2024	The Manufacturers Life Insurance Company	486,023	$1.36M	0.0%	+1.2%	0.232%
11/9/2024	Intech Investment Management LLC	41,331	$0.12M	0.0%	N/A	0.020%
11/6/2024	Cornercap Investment Counsel Inc.	28,533	$80K	0.0%	-55.0%	0.014%
11/6/2024	Curi RMB Capital LLC	149,577	$0.42M	0.0%	+47.5%	0.072%
10/25/2024	China Universal Asset Management Co. Ltd.	40,219	$0.11M	0.0%	+64.0%	0.019%
10/22/2024	Private Advisor Group LLC	12,087	$34K	0.0%	N/A	0.006%
10/11/2024	Creative Planning	61,396	$0.17M	0.0%	+108.7%	0.029%
10/10/2024	Exchange Traded Concepts LLC	60,675	$0.17M	0.0%	+25.5%	0.029%
10/3/2024	SG Americas Securities LLC	46,967	$0.13M	0.0%	+252.7%	0.022%
8/16/2024	Perceptive Advisors LLC	2,725,000	$6.35M	0.2%	N/A	1.304%
8/16/2024	Algert Global LLC	14,808	$35K	0.0%	N/A	0.007%
8/15/2024	Susquehanna Fundamental Investments LLC	418,699	$0.98M	0.0%	+46.2%	0.200%
8/15/2024	Lynx1 Capital Management LP	2,228,295	$5.19M	1.9%	N/A	1.066%
8/15/2024	The Manufacturers Life Insurance Company	480,381	$1.12M	0.0%	+70.3%	0.230%
8/15/2024	AQR Capital Management LLC	27,287	$64K	0.0%	N/A	0.013%
8/15/2024	Caxton Associates LP	466,110	$1.09M	0.0%	+8.1%	0.223%
8/14/2024	Squarepoint Ops LLC	126,628	$0.30M	0.0%	N/A	0.061%
8/14/2024	Profund Advisors LLC	76,160	$0.18M	0.0%	-37.1%	0.036%
8/12/2024	Hsbc Holdings PLC	44,664	$0.10M	0.0%	-17.5%	0.021%
8/12/2024	E Fund Management Co. Ltd.	25,333	$59K	0.0%	-31.8%	0.012%
8/9/2024	Primecap Management Co. CA	5,670,226	$13.21M	0.0%	+4.1%	2.713%

Data available starting January 2016

See Full Table

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.55

$1.51

$1.69

50 Day Range

MA: $1.86

$1.40

$2.83

52 Week Range

Now: $1.55

$1.32

$4.45

Volume

2,011,066 shs

Average Volume

3,137,745 shs

Market Capitalization

$336.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Who are the company insiders with the largest holdings of Allogene Therapeutics?: Allogene Therapeutics' top insider shareholders include:
David D Chang (CEO)
Arie Belldegrun (Director)
Geoffrey M Parker (CFO)
Earl Martin Douglas (SVP)
Zachary Roberts (EVP)
Franz B Humer (Director)
Timothy L Moore (Insider)
Benjamin Machinas Beneski (SVP)
Deborah M Messemer (Director)
Stephen Mayo (Director)
Learn More about top insider investors at Allogene Therapeutics.
Who are the major institutional investors of Allogene Therapeutics?: Allogene Therapeutics' top institutional shareholders include:
Lynx1 Capital Management LP — 5.19%
Vanguard Group Inc. — 3.82%
Primecap Management Co. CA — 2.35%
Price T Rowe Associates Inc. MD — 2.14%
JPMorgan Chase & Co. — 1.78%
Dimensional Fund Advisors LP — 1.70%
Learn More about top institutional investors of Allogene Therapeutics stock.
Which institutional investors are selling Allogene Therapeutics stock?: During the previous quarter, ALLO stock was sold by these institutional investors:
Primecap Management Co. CA
Price T Rowe Associates Inc. MD
JPMorgan Chase & Co.
Vanguard Group Inc.
Jane Street Group LLC
Coastal Bridge Advisors LLC
Squarepoint Ops LLC
Partners Capital Investment Group LLP
Within the previous year, company insiders that have sold Allogene Therapeutics company stock include:
David D Chang (CEO)
Arie Belldegrun (Director)
Geoffrey M Parker (CFO)
Earl Martin Douglas (SVP)
Zachary Roberts (EVP)
Franz B Humer (Director)
Timothy L Moore (Insider)
Benjamin Machinas Beneski (SVP)
Learn More investors selling Allogene Therapeutics stock.
Which institutional investors are buying Allogene Therapeutics stock?: During the previous quarter, ALLO stock was acquired by institutional investors including:
Lynx1 Capital Management LP
Foresite Capital Management VI LLC
Patient Square Capital LP
Gilead Sciences Inc.
Dimensional Fund Advisors LP
BNP Paribas Financial Markets
Bank of America Corp DE
Raiffeisen Bank International AG
Within the previous year, these company insiders have bought Allogene Therapeutics stock:
David D Chang (CEO)
Arie Belldegrun (Director)
Learn More investors buying Allogene Therapeutics stock.